Evaluation of Major and Minor Hemorrhagic Events in Various Dual Antiplatelet Therapy after Percutaneous Coronary Intervention

Abstract

Coronary disease is a relatively common cause of mortality among patients in developing countries and is one of major problem of health care system. Also, hemorrhagic events after percutaneous coronary intervention (PCI) are important and relatively common complications. The aim of present study was to evaluate major and minor hemorrhagic events in dual antiplatelet therapy after PCI with various clopidogrel brands in Iranian pharmaceutical market. Materials and methods: In a descriptive analytical study, 900 patients whom PPCI done for them in Shahid Madani Hospital Educational Medical Center of Tabriz University of Medical Sciences and they were under dual antiplatelet therapy were included the study and evaluated. 300 patients were under treatment with Osvix, 300 patients under treatment with Plavix, and 300 patients Zyllt. Patients were followed up 6 months after admission, and the frequency of major and minor hemorrhagic events of the patients were evaluated. Results: The three groups of study did not have a significant difference in terms of demographic factors and risk factors of heart disease. CNS hemorrhages were observed in 1 patient (0.3%) in Osvix group, 2 patients (0.7%) in Plavix group, and 2 patients (0.7%) in Zyllt. Gastrointestinal bleeding was also observed in 4 cases (1.3%) in Osvix group, 2 patients (0.7%) in Plavix group, and 2 cases (0.7%) in Zyllt group. The three groups of study did not show significant differences in the frequency of major and minor hemorrhagic events during 6 months follow up.